Stereotactic body radiation therapy in elderly patients with spinal metastases - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Stereotactic Body Radiotherapy for Older Adults With Spinal Metastases

  • By

  • Brock J. Gjesdal

  • Samuel Adida

  • Suchet Taori

  • Andrew H. Zureick

  • Serah Choi

  • John C. Flickinger

  • Pascal O. Zinn

  • James C. Bayley

  • Peter C. Gerszten

  • Roberta K. Sefcik

  • October 16, 2026

Share

  • 1

    This retrospective study evaluated SBRT outcomes in 161 patients aged 70 years or older with 208 spinal metastases treated at one center from 2002 to 2024.

  • 2

    SBRT was delivered alone or with decompression and stabilization, with treatment selection individualized according to neurologic findings, epidural disease, spinal stability, and other clinical facto

  • 3

    The study assessed local failure, vertebral compression fracture, pain response, and radiation toxicity using clinical follow-up and imaging.

  • 4

    Local failure required radiographic progression at the treated level, assessed by a neurosurgeon or neuroradiologist and confirmed on subsequent imaging.

  • 5

    Vertebral compression fracture included a new fracture or progression of a pre-existing fracture at any treated level after SBRT, regardless of attribution.

Original Source(s)

Stereotactic body radiation therapy in elderly patients with spinal metastases

  • by Brock J. Gjesdal, Samuel Adida, Suchet Taori, Andrew H. Zureick, Serah Choi, John C. Flickinger, Pascal O. Zinn, James C. Bayley, Peter C. Gerszten, Roberta K. Sefcik

  • October 16, 2026

Related Content

Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors: A Secondary

CRISPR-Based Delivery System Generates CAR T Cells In Vivo

A two-vector delivery system generates tumor-targeting CAR T cells directly inside the body, achieving complete responses in mouse cancer models

  • October 13, 2026

  • 3 min
Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance